Clinical Trial Update: Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer [NA]

View source ↗

Summary

A Phase II neoadjuvant trial evaluating FEC100/Cisplatin-Docetaxel with or without trastuzumab in HER2-positive locally advanced breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: King Faisal Specialist Hospital & Research Center | Conditions: Breast Cancer | NA | Status: COMPLETED